ClinicalTrials.gg
Active, not recruitingNCT05626491rtACSUpdated Oct 9, 2026

Electrical Stimulation for the Treatment of Glaucoma

An interventional study of Repetitive, Transorbital Alternating Current Stimulation (rtACS) and Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS) in Glaucoma and Glaucoma, Open-Angle, sponsored by Stanford University. Active, not recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Primary conditionGlaucoma, Open-AngleRegistry: GlaucomaReclassifiedWhy we changed it
Registry
Glaucoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glaucoma, Open-Angle
Why
  1. The study's listed conditions name Glaucoma, Open-Angle, a narrower term within Glaucoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 9, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 348 studies in Glaucoma, Open-Angle with a site in United States — 49 open to participants now, 67 under way, 5 of them phase 3. Glaucoma, Open-Angle · United States.

Planned enrollment
197th of 279
45 · median 84
Started
2023
with 13 others
No phase
82 of 348
14 open now
Primary completion
2026-12
later than 24 of 66 live
Registered
281st of 348
by date

Among the 348 studies in Glaucoma, Open-Angle with a site in United States, this one is the 197th largest by planned enrollment of the 279 interventional ones that give a count, is one of 14 that started in 2023, is one of 82 with no phase, reaches primary completion later than 24 of the 66 other live ones, and was the 281st registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

49 of the 348 studies in Glaucoma, Open-Angle with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 348 studies in Glaucoma, Open-Angle with a site in United States, or all of them as a file.
02

Study summary

The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.

03

Conditions studied

  • Glaucoma
  • Glaucoma, Open-Angle

Browse trials for

04

In context

Glaucoma, Open-Angle Reclassified

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

This study's planned enrollment of 45 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.

Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.

Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glaucoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be at least 18.
  2. Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE).
  3. Participant's clinical diagnosis must be consistent with glaucoma characterized by the following features: Mean deviation (MD) worse than -3 on Humphrey Visual Field 24-2 testing. Reliable visual field measures, fixation losses do not exceed 20% and false positives do not exceed 20%.
  4. Visual Field Index between 10 and 90%
  5. Corrected visual acuity ≥ 1.00 (logMAR), 20/200 (Snellen), 0.10 (decimal)
  6. In the opinion of the investigator the participant's eye pressure must be clinically stable.
  7. If a participant has two eyes meeting study criteria, the worse eye as determined by mean deviation. If both eyes qualify and have the same MD, the patient may choose which eye they are willing to enter, or else a randomization procedure will assign one eye to the study.
  8. Participant must understand and sign the . If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.

Exclusion criteria

Exclusion Criteria:

  1. Participant is unable to comply with study procedures or follow-up visits.
  2. Participant has a history of ocular herpes zoster.
  3. Participant has pathological nystagmus
  4. Participant has evidence of visually significant retinopathy including but not limited to Diabetic retinopathy or retinitis pigmentosa.
  5. Participant has evidence of corneal opacification or lack of optical clarity.
  6. Participant has uveitis or other ocular inflammatory disease.
  7. Participant has any electric or electronic implants such as a pacemaker.
  8. Participant has acute conjunctivitis.
  9. Participant has acute disease.
  10. Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a drug by ocular (if in the study eye) or systemic administration.
  11. Participant is pregnant or lactating.
  12. Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments. Including but not limited to all forms of dementia.
  13. Unresected brain tumors
  14. Implanted intracranial magnetic metals (metallic implants in the head / skull such as clamps, coils, ventriculo-peritoneal shunts, endoprostheses, etc.), which are not MRI-compatible. Note: metallic dental implants and titanium screws or plates are acceptable
  15. Patients with any skin damage.
  16. Children and comatose patients.
  17. Patients with history of epileptic seizure within the last 10 years.
  18. Patients with uncontrolled systemic hypertension or uncontrolled diabetes.
  19. Self-reported alcohol or illicit drug addictions within the last 12 months.
  20. Participant is not able to travel, to comply with the requirements of the study or not willing to complete the schedule of events (SOE) and/or unable to confirm follow-up participation
  21. Prior participation in a vision training/stimulation study in the last 12 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Active SAVIR Alpha Synch Mobile device (SASm)

    Patients will receive active treatment with the device every other day over 8 weeks.

    Device: Repetitive, Transorbital Alternating Current Stimulation (rtACS)

  • Sham comparator
    Sham SAVIR Alpha Synch Mobile device (SASm)

    Patients will receive sham treatment (no active stimulation) with the device every other day over 8 weeks.

    Device: Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS)

Interventions

  • DeviceRepetitive, Transorbital Alternating Current Stimulation (rtACS)

    Patients receive treatment every other day via a headband that delivers electrical stimulation to the retina

    Also known as: Electrical Stimulation

  • DeviceSham Repetitive, Transorbital Alternating Current Stimulation (rtACS)

    Patients receive sham treatment (no active stimulation) every other day via a headband.

07

What researchers measure

Primary outcomes

  1. Change from baseline in visual field assessed by Humphrey Visual Field Index (VFI).

    Time frame: Baseline through 6 months

Secondary outcomes

  1. Change from baseline in visual field assessed by Humphrey Mean Deviation (MD).

    Time frame: Baseline through 6 months

  2. Change from baseline in visual field assessed by Pelli-Robson Contrast Sensitivity.

    Pelli-Robson is a standard for measuring contrast sensitivity. It is measured on a 0-16 scale. Normal contrast sensitivity is between 12 and 14 with 0 being worst and 16 being best.

    Time frame: Baseline through 6 months

  3. Change from baseline in visual acuity as assessed by the Snellen visual acuity test.

    The Snellen test is a standard eye chart test used to test eyesight.

    Time frame: Baseline through Month 6

08

Study locations

4 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2026, 46 months after the start.

Of 101 non-industry interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 46 months is above that.

Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2026 → Jun 2027, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2022
First posted
Nov 23, 2022
StartActual
Feb 28, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027was Dec 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Dec 2026→Jun 2027
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Study completion Dec 2026→Jun 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05626491
Collaborators
NYU Langone Health, Otto-von-Guericke University Magdeburg, Wills Eye
Responsible party
Jeffrey L Goldberg (Professor of Ophthalmology, Stanford University) — Principal investigator
First posted
Nov 23, 2022
Start date
Feb 28, 2023
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Jeffrey L Goldberg, MD PhD
principal investigator · Stanford University
Bernhard Sable, PhD
principal investigator · Otto-von-Guericke University Magdeburg
Joeseph F Panarelli, MD
principal investigator · NYU- Langone
Joel Schuman, MD,FACS
principal investigator · Wills Eye

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion